Patents Assigned to Xeris Pharmaceuticals Inc.
-
Patent number: 11964003Abstract: The present invention relates to the use of aprotic polar solvents and an ionization stabilizing agent to prepare storage stable sustained release therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be administered to patients suffering from or predisposed to a variety of physical conditions or disorders, notably hypoglycemia.Type: GrantFiled: June 25, 2021Date of Patent: April 23, 2024Assignee: XERIS PHARMACEUTICALS, INC.Inventors: Evan Cassavaugh, Steven Prestrelski
-
Patent number: 11957736Abstract: The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare device compatible stable therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be used with various devices (e.g., pumps, infusion sets) for administration of the formulation. In certain embodiments, the invention is directed to formulations comprising one or more therapeutic agents, as well as methods of making such formulations, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system, such as a DMSO/water admixture, comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.Type: GrantFiled: February 13, 2023Date of Patent: April 16, 2024Assignee: Xeris Pharmaceuticals, inc.Inventors: Martin Donovan, Wendy Hu
-
Publication number: 20240041984Abstract: Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.Type: ApplicationFiled: March 7, 2023Publication date: February 8, 2024Applicant: Xeris Pharmaceuticals, Inc.Inventors: Steven PRESTRELSKI, Michael SANDOVAL, Martin DONOVAN
-
Publication number: 20240016898Abstract: Certain embodiments are directed to methods for treating, ameliorating, or preventing exercise-induced or exercise-associated hypoglycemia comprising administration to a subject in need thereof a formulation(s) of glucagon or glucagon analog in an amount effective to treat, ameliorate, or prevent the condition. The subject can be administered a glucagon or a glucagon analog composition 1, 5, 10, 15 to 20, 25, 30 minutes prior to initiation of exercise.Type: ApplicationFiled: July 24, 2023Publication date: January 18, 2024Applicant: Xeris Pharmaceuticals, Inc.Inventors: Steven PRESTRELSKI, Brett NEWSWANGER, Martin CUMMINS, Michael RIDDELL
-
Patent number: 11833157Abstract: Embodiments of the invention are directed to formulations that provide a solution to the problem of small molecule (e.g., diazepam) precipitation at the injection site when administered as a highly-concentrated formulation. In certain aspects the formulations include at least one surfactant in a non-aqueous formulation, which prevents small molecule precipitation and improves the bioavailability of the drug by enhancing absorption into the systemic circulation.Type: GrantFiled: May 13, 2021Date of Patent: December 5, 2023Assignee: Xeris Pharmaceuticals, Inc.Inventors: Steven J. Prestrelski, Michael A. Sandoval, Brian R. Sloat
-
Publication number: 20230346891Abstract: The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare device compatible stable therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be used with various devices (e.g., pumps, infusion sets) for administration of the formulation. In certain embodiments, the invention is directed to formulations comprising one or more therapeutic agents, as well as methods of making such formulations, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system, such as a DMSO/water admixture, comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.Type: ApplicationFiled: February 13, 2023Publication date: November 2, 2023Applicant: Xeris Pharmaceuticals, inc.Inventors: Martin DONOVAN, Wendy HU
-
Publication number: 20230085357Abstract: The present invention provides compositions comprising one or more active pharmaceutical ingredients, wherein the compositions are in the form of high solids concentration pastes capable of being injected in relatively low volumes into an animal using standard commercially available syringes. The invention also provides methods of making such compositions, particularly those compositions comprising high molecular weight active ingredients (e.g., antibodies, enzymes and other proteins and peptides) at relatively high therapeutic concentrations in the high solids concentration pastes. The invention further provides methods of using such formulations in treating, preventing and/or ameliorating certain diseases and physical disorders in animals, including humans, in need thereof. The invention also provides kits comprising the formulations of the invention and a suitable syringe, which in some aspects may be pre-loaded or pre-filled with a composition of the invention.Type: ApplicationFiled: September 9, 2022Publication date: March 16, 2023Applicant: Xeris Pharmaceuticals, Inc.Inventors: Martin DONOVAN, Steven PRESTRELSKI, Scott COLEMAN, Brian SLOAT, Diana BOWMAN, Richard FITCH
-
Patent number: 11590205Abstract: Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.Type: GrantFiled: September 25, 2016Date of Patent: February 28, 2023Assignee: Xeris Pharmaceuticals, Inc.Inventors: Steven Prestrelski, Martin Donovan, Michael Sandoval
-
Patent number: 11576951Abstract: The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare device compatible stable therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be used with various devices (e.g., pumps, infusion sets) for administration of the formulation. In certain embodiments, the invention is directed to formulations comprising one or more therapeutic agents, as well as methods of making such formulations, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system, such as a DMSO/water admixture, comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.Type: GrantFiled: May 29, 2020Date of Patent: February 14, 2023Assignee: XERIS PHARMACEUTICALS, INC.Inventors: Martin Donovan, Wendy Hu
-
Patent number: 11446310Abstract: Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 ?l to 3 ml.Type: GrantFiled: July 31, 2020Date of Patent: September 20, 2022Assignee: Xeris Pharmaceuticals, Inc.Inventors: Steven J. Prestrelski, Nancy Scott
-
Patent number: 11129940Abstract: This disclosure includes syringes, kits containing the same, and related methods. Some syringes are pre-loaded with paste and have a syringe body defining a reservoir having an internal first transverse dimension, a paste disposed within the reservoir, the paste having a solids concentration of greater than 50 mg/mL, a needle defining a lumen having an internal second transverse dimension that is smaller than the first transverse dimension, the needle configured to be in fluid communication with the reservoir to allow intracutaneous delivery of the paste, and a plunger and/or piston disposed within the reservoir and configured to be moved to dispense paste from the reservoir through the lumen. Some syringes include a fitting (e.g. Luer fitting) disposed on the syringe body and in fluid communication with the reservoir and a sealing cap disposed on the Luer fitting to seal the reservoir.Type: GrantFiled: August 6, 2015Date of Patent: September 28, 2021Assignee: Xeris Pharmaceuticals, Inc.Inventor: Martin Donovan
-
Patent number: 11020403Abstract: Embodiments of the invention are directed to formulations that provide a solution to the problem of small molecule (e.g., diazepam) precipitation at the injection site when administered as a highly-concentrated formulation. In certain aspects the formulations include at least one surfactant in a non-aqueous formulation, which prevents small molecule precipitation and improves the bioavailability of the drug by enhancing absorption into the systemic circulation.Type: GrantFiled: May 31, 2018Date of Patent: June 1, 2021Assignee: Xeris Pharmaceuticals, Inc.Inventors: Steven J. Prestrelski, Michael A. Sandoval, Brian R. Sloat
-
Patent number: 10987399Abstract: Stable formulations for parenteral injection of peptide drugs and methods of using such stable formulations are provided. In particular, the present invention provides stable formulations for parenteral injection of glucagon and methods of using such glucagon formulations to treat hypoglycemia, especially severe hypoglycemia in emergency situations.Type: GrantFiled: March 22, 2016Date of Patent: April 27, 2021Assignee: XERIS PHARMACEUTICALS, INC.Inventors: Steven Prestrelski, John Kinzell
-
Publication number: 20210030847Abstract: Post-bariatric hypoglycemia (PBH) is an increasingly-recognized complication of gastric bypass surgery. Current therapeutic options have suboptimal efficacy. Small doses of stable liquid glucagon can be used to treat or prevent post-bariatric hypoglycemia.Type: ApplicationFiled: January 23, 2019Publication date: February 4, 2021Applicants: XERIS PHARMACEUTICALS, INC., Joslin Diabetes Center, Inc.Inventors: Brett NEWSWANGER, Steven J. PRESTRELSKI, Mary-Elizabeth PATTI
-
Publication number: 20210008170Abstract: Certain embodiments are directed to methods for treating, ameliorating, or preventing exercise-induced or exercise-associated hypoglycemia comprising administration to a subject in need thereof a formulation(s) of glucagon or glucagon analog in an amount effective to treat, ameliorate, or prevent the condition. The subject can be administered a glucagon or a glucagon analog composition 1, 5, 10, 15 to 20, 25, 30 minutes prior to initiation of exercise.Type: ApplicationFiled: December 21, 2018Publication date: January 14, 2021Applicant: XERIS PHARMACEUTICALS, INC.Inventors: Steven PRESTRELSKI, Brett NEWSWANGER, Martin CUMMINS, Michael RIDDELL
-
Publication number: 20200376083Abstract: The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare device compatible stable therapeutic formulations by dissolving a therapeutic agent (active ingredient) in an aprotic polar solvent system that can then be used with various devices (e.g., pumps, infusion sets) for administration of the formulation. In certain embodiments, the invention is directed to formulations comprising one or more therapeutic agents, as well as methods of making such formulations, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system, such as a DMSO/water admixture, comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.Type: ApplicationFiled: May 29, 2020Publication date: December 3, 2020Applicant: XERIS PHARMACEUTICALS, INC.Inventors: Martin DONOVAN, Wendy HU
-
Publication number: 20200368250Abstract: Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 ?l to 3 ml.Type: ApplicationFiled: July 31, 2020Publication date: November 26, 2020Applicant: Xeris Pharmaceuticals, Inc.Inventors: Steven J. PRESTRELSKI, Nancy SCOTT
-
Patent number: 10765683Abstract: Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 ?l to 3 ml.Type: GrantFiled: July 29, 2015Date of Patent: September 8, 2020Assignee: Xeris Pharmaceuticals, Inc.Inventors: Steven J. Prestrelski, Nancy Scott
-
Patent number: 10485850Abstract: Certain embodiments are directed to a formulation of a therapeutic agent, as well as a method of making such a formulation, comprising at least one therapeutic agent dissolved in an aprotic polar solvent system comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent.Type: GrantFiled: May 15, 2017Date of Patent: November 26, 2019Assignee: XERIS PHARMACEUTICALS, INC.Inventors: Steven Prestrelski, Michael Sandoval, Martin Donovan
-
Patent number: 9687527Abstract: The delivery of biopharmaceutical and other therapeutic agents parenterally to an animal via a minimally invasive, low pain administration is provided. The agents are delivered to the patient via, e.g., the epidermal, dermal, or subcutaneous layer of the skin in a concentrated form of injectable glucagon that is dissolved in a pharmaceutically acceptable carrier.Type: GrantFiled: February 21, 2014Date of Patent: June 27, 2017Assignees: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE, XERIS PHARMACEUTICALS, INC.Inventors: Steven Prestrelski, Wei-Jie Fang, John F. Carpenter, John Kinzell